Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India

Background. In 2002, the Meningitis Vaccine Project (MVP) chose the Serum Institute of India, Ltd (SIIL), as its manufacturing partner to establish a product development partnership (PDP) with the Meningitis Vaccine Project (MVP). MVP was a collaboration between PATH and the World Health Organizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Prasad S., Socquet, Muriel, Jadhav, Suresh S., Kapre, Subhash V., LaForce, F. Marc, Poonawalla, Cyrus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639485/
https://www.ncbi.nlm.nih.gov/pubmed/26553678
http://dx.doi.org/10.1093/cid/civ500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639485/
https://www.ncbi.nlm.nih.gov/pubmed/26553678
http://dx.doi.org/10.1093/cid/civ500

Ejemplares similares